HRP20110938T1 - Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora - Google Patents

Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora Download PDF

Info

Publication number
HRP20110938T1
HRP20110938T1 HR20110938T HRP20110938T HRP20110938T1 HR P20110938 T1 HRP20110938 T1 HR P20110938T1 HR 20110938 T HR20110938 T HR 20110938T HR P20110938 T HRP20110938 T HR P20110938T HR P20110938 T1 HRP20110938 T1 HR P20110938T1
Authority
HR
Croatia
Prior art keywords
4alkyl
compound
optionally substituted
independently selected
thiophenyl
Prior art date
Application number
HR20110938T
Other languages
English (en)
Croatian (hr)
Inventor
Ji Yu-Hua
Husfeld Craig
Mu Yongqi
Lee Rick
Li Li
Original Assignee
Theravance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance filed Critical Theravance
Publication of HRP20110938T1 publication Critical patent/HRP20110938T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
HR20110938T 2007-09-07 2008-09-05 Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora HRP20110938T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96791407P 2007-09-07 2007-09-07
PCT/US2008/010431 WO2009035542A2 (en) 2007-09-07 2008-09-05 Guanidine-containing compounds useful as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20110938T1 true HRP20110938T1 (hr) 2012-01-31

Family

ID=40139105

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110938T HRP20110938T1 (hr) 2007-09-07 2008-09-05 Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora

Country Status (20)

Country Link
US (5) US7960385B2 (de)
EP (1) EP2197841B1 (de)
JP (1) JP5656288B2 (de)
KR (1) KR101517574B1 (de)
CN (1) CN101796026B (de)
AT (1) ATE531692T1 (de)
AU (1) AU2008299993B2 (de)
BR (1) BRPI0816219B8 (de)
CA (1) CA2697752C (de)
CY (1) CY1112255T1 (de)
DK (1) DK2197841T3 (de)
ES (1) ES2375516T3 (de)
HR (1) HRP20110938T1 (de)
IL (1) IL204064A (de)
MX (1) MX2010002576A (de)
PL (1) PL2197841T3 (de)
PT (1) PT2197841E (de)
RU (1) RU2480458C2 (de)
SI (1) SI2197841T1 (de)
WO (1) WO2009035542A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2675942C (en) * 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
US8202891B2 (en) 2007-04-24 2012-06-19 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
JP5656288B2 (ja) * 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
US8017617B2 (en) 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
WO2012048154A1 (en) 2010-10-06 2012-04-12 Biocare Medical, Llc Methods and systems for efficient processing of biological samples
US9945763B1 (en) 2011-02-18 2018-04-17 Biocare Medical, Llc Methods and systems for immunohistochemistry heat retrieval of biological samples
UA115989C2 (uk) 2012-07-05 2018-01-25 Арвен Айлак Санайі Ве Тіджарет А.С. Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
CN104876854B (zh) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 羟基乙酸酯衍生物及其用途
WO2016173817A1 (en) 2015-04-28 2016-11-03 Unilever Plc N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same
US10307355B2 (en) 2015-04-28 2019-06-04 Conopco, Inc. N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same
EP3625232B1 (de) 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituierte methanopyrido[2,1-a]isoindolone als machr-modulatoren zur behandlung verschiedener assoziierter pathophysiologischer zustände und verfahren zur herstellung davon

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732247A (en) * 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
IT8721978A0 (it) 1987-09-21 1987-09-21 Angeli Inst Spa Nuovi derivati ammidinici triciclici.
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
DE19743435A1 (de) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
HRP20000495B1 (en) * 1998-02-04 2005-12-31 Banyu Pharmaceutical Co. N-acyl cyclic amine derivatives
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE60021282T2 (de) 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
EP1302458A4 (de) * 2000-07-11 2005-10-19 Banyu Pharma Co Ltd Esterderivate
DE60121813T2 (de) * 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
DE10216339A1 (de) * 2002-04-13 2003-10-23 Boehringer Ingelheim Pharma Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
AU2002347552A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
PE20050231A1 (es) * 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
ES2239546B1 (es) 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
WO2006005980A1 (en) 2004-06-16 2006-01-19 Ranbaxy Laboratories Limited Xanthine derivatives useful as muscarinic receptor antagonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428418D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
JP2009504624A (ja) 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
CA2675942C (en) * 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
US8202891B2 (en) 2007-04-24 2012-06-19 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
JP5656288B2 (ja) * 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
US8017617B2 (en) 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists

Also Published As

Publication number Publication date
PT2197841E (pt) 2012-01-02
US7960385B2 (en) 2011-06-14
AU2008299993A1 (en) 2009-03-19
PL2197841T3 (pl) 2012-04-30
US20110319448A1 (en) 2011-12-29
EP2197841A2 (de) 2010-06-23
ATE531692T1 (de) 2011-11-15
US8198304B2 (en) 2012-06-12
CN101796026A (zh) 2010-08-04
US20130267706A1 (en) 2013-10-10
ES2375516T3 (es) 2012-03-01
US8338424B2 (en) 2012-12-25
JP2010538070A (ja) 2010-12-09
US20090069335A1 (en) 2009-03-12
MX2010002576A (es) 2010-04-01
IL204064A (en) 2014-07-31
EP2197841B1 (de) 2011-11-02
WO2009035542A2 (en) 2009-03-19
KR20100081309A (ko) 2010-07-14
RU2010113358A (ru) 2011-10-20
US20110201583A1 (en) 2011-08-18
KR101517574B1 (ko) 2015-05-07
AU2008299993B2 (en) 2013-09-05
RU2480458C2 (ru) 2013-04-27
CN101796026B (zh) 2013-10-23
BRPI0816219B1 (pt) 2018-11-06
CA2697752C (en) 2016-01-26
SI2197841T1 (sl) 2012-02-29
HK1144433A1 (en) 2011-02-18
CA2697752A1 (en) 2009-03-19
US8039489B2 (en) 2011-10-18
BRPI0816219B8 (pt) 2021-05-25
CY1112255T1 (el) 2015-12-09
JP5656288B2 (ja) 2015-01-21
DK2197841T3 (da) 2012-02-06
US8785633B2 (en) 2014-07-22
BRPI0816219A2 (pt) 2015-06-16
US20120219509A1 (en) 2012-08-30
WO2009035542A3 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
HRP20110938T1 (hr) Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora
JP2021534124A5 (de)
HRP20241020T1 (hr) Makrociklički spoj koji služi kao wee1 inhibitor i njegove primjene
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
PE20040644A1 (es) Nuevos derivados de quinuclidina-amina
HRP20110590T1 (hr) Spojevi 8-azabiciklo[3.2.1]oktana kao antagonisti mu opioidnih receptora
UY25842A1 (es) Antagonistas de receptores de il-8
HRP20131095T1 (hr) Derivati benzazepina korisni kao antagonisti vazopresina
JP2006524660A5 (de)
JP2009504764A5 (de)
EA201391158A8 (ru) Диаминиевые соли фенотиазина и их применение
JP2020517677A5 (de)
HRP20171914T1 (hr) Postupak za dobivanje spojeva koji su korisni kao inhibitori sglt
LU90011I2 (fr) Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
MX2008000115A (es) Derivados de piperidina utiles como antagonistas de histamina h3.
AR067060A1 (es) Derivados de guanina policiclicos y sus metodos de uso
WO2017072341A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
RU2011108008A (ru) Производные трициклического алкиламинометилоксазолидинона
AR072611A1 (es) Compuestos de 3-(fenoxifenilmetil)pirrolidina, un metodo para su preparacion, intermediario de sintesis y su proceso de obtencion, composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de 5-ht y ne.
RU2020132293A (ru) Амидные пролекарства низкомолекулярных модуляторов ядерных рецепторов
RU2007116987A (ru) Новые соединения